Get the Stockscreener App
3.78
2.33%
-0.09
Molecular Partners AG ADR stock is currently priced at $3.78, with a 24-hour trading volume of 537.
It has seen a -2.33% decreased in the last 24 hours and a -3.32% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $3.87 pivot point. If it approaches the $3.87 support level, significant changes may occur.
Previous Close:
$3.87
Open:
$3.8
24h Volume:
537
Market Cap:
$124.24M
Revenue:
$7.80M
Net Income/Loss:
$-69.02M
P/E Ratio:
-1.8743
EPS:
-2.0168
Net Cash Flow:
$-66.61M
1W Performance:
-0.53%
1M Performance:
-3.32%
6M Performance:
-12.90%
1Y Performance:
-41.85%
1D Range:
$3.75
$3.80
52W Range:
$3.32
$7.32
Molecular Partners AG ADR Stock (MOLN) Company Profile
Name
Molecular Partners AG ADR
Sector
Industry
Phone
41 44 755 77 00
Address
Wagistrasse 14, Schlieren
Molecular Partners AG ADR Stock (MOLN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-30-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-29-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-25-22 | Upgrade | Credit Suisse | Underperform → Neutral |
| Apr-27-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-12-21 | Resumed | SVB Leerink | Outperform |
View All
Molecular Partners AG ADR Stock (MOLN) Latest News
Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program
GlobeNewswire Inc.
Novartis (NVS) & Molecular Partners Initiate Study for COVID-19 - Yahoo Singapore News
Yahoo Singapore News
Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action
GlobeNewswire Inc.
Life Science Cares Launches in Switzerland
GlobeNewswire Inc.
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
GlobeNewswire Inc.
Molecular Partners Publishes Invitation to Annual General Meeting 2024
GlobeNewswire Inc.
Molecular Partners AG ADR Stock (MOLN) Financials Data
Molecular Partners AG ADR (MOLN) Revenue 2024
MOLN reported a revenue (TTM) of $7.80 million for the quarter ending December 31, 2023, a -96.19% decline year-over-year.
Molecular Partners AG ADR (MOLN) Net Income 2024
MOLN net income (TTM) was -$69.02 million for the quarter ending December 31, 2023, a -153.42% decrease year-over-year.
Molecular Partners AG ADR (MOLN) Cash Flow 2024
MOLN recorded a free cash flow (TTM) of -$66.61 million for the quarter ending December 31, 2023, a -154.23% decrease year-over-year.
Molecular Partners AG ADR (MOLN) Earnings per Share 2024
MOLN earnings per share (TTM) was -$2.1044 for the quarter ending December 31, 2023, a -154.36% decline year-over-year.
About Molecular Partners AG ADR
Molecular Partners AG operates as a clinical-stage biopharmaceutical company. It is developing Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration, as well as for diabetic macular edema; and MP0250 that binds and inhibit vascular endothelial growth factor and hepatocyte growth factor pathways, which restores clinical sensitivity to various standard-of-care therapies in multiple myeloma. The company is also developing MP0274 that is in Phase I clinical trials for HER2-positive solid tumors; MP0310, which is in Phase I clinical trials for immuno-oncology; MPO317, a tumor-localized immune agonist that activates immune cells in the tumor; and Peptide-MHC, a tumor-localized immune-cell agonist to attack tumors. It has strategic partnerships with Allergan, Inc. and Amgen SA; and collaboration with AGC Biologics to develop anti-COVID-19 DARPin program. Molecular Partners AG was founded in 2004 and is headquartered in Schlieren, Switzerland.
0.77%
1.20%
Cap:
|
Volume (24h):